FDA Accelerated Approval in Oncology: A Strategic Guide for Biopharma

The development of oncology therapeutics is often marked by biological complexity and long timelines required to demonstrate definitive clinical benefit. To address situations in which patients cannot wait for traditional outcome data, the U.S. Food and Drug Administration (FDA) established the Accelerated Approval (AA) pathway, which enables earlier approval of drugs that treat serious and life-threatening conditions and address unmet medical needs based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit. ¹

Although applicable across multiple therapeutic areas, over 80% of accelerated approvals has been granted to oncology therapies, reflecting both the rapid pace of scientific innovation and the persistent unmet need in cancer care. ² For biopharmaceutical companies, accelerated approval represents a powerful but conditional regulatory mechanism, one that can expedite patient access while requiring rigorous development planning, disciplined execution of confirmatory studies, and a sustained commitment to evidence generation.

What Is FDA Accelerated Approval?

The accelerated approval pathway was formally established in 1992 under Subpart H (21 CFR 314.500) and allows FDA to approve drugs for serious or life‑threatening conditions based on surrogate endpoints or intermediate clinical endpoints that are reasonably likely to predict clinical benefit. ³

In oncology, commonly accepted surrogate endpoints have included objective response rate (ORR), duration of response (DoR), minimal residual disease (MRD) negativity in hematologic malignancies, and event‑free survival in selected settings, provided that scientific evidence supports their relevance to meaningful clinical outcomes. ⁴

Accelerated approval does not reduce the standard for safety or manufacturing quality. Instead, it shifts the timing of efficacy confirmation, requiring sponsors to conduct post‑marketing confirmatory trials to verify and describe clinical benefit.

It is important to note that, while FDA accelerated approval provides an important pathway for earlier access to therapies in the United States, it is a U.S.-specific regulatory mechanism that allows approval based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit, with confirmatory trials required post-approval. In oncology specifically, the FDA has stated that response rate is the most frequently used endpoint to support accelerated approval when approval is based on data from single-arm trials. ^{5, 6}

In the European Union, expedited pathways exist (e.g., Conditional Marketing Authorisation), but EU law and EMA’s framework explicitly operate in a setting where “comprehensive clinical data” are normally expected, with conditional approvals granted under defined circumstances and obligations to provide missing data. ^{7, 8} As a result, sponsors planning a global submission strategy generally need an evidence plan that can satisfy non-U.S. regulators and, critically, health technology assessment (HTA) and payer requirements, which often demand evidence that answers comparative effectiveness questions that single-arm and surrogate-endpoint packages may not resolve. ⁹

It is also important to recognise that FDA accelerated approval does not inherently shorten the statutory FDA review timeline. Accelerated Approval is an evidentiary pathway that allows approval based on surrogate or intermediate clinical endpoints, but it does not modify the standard PDUFA review clock. For a new drug or biologics application, the FDA’s standard review goal is 10 months from filing (commonly described as approximately 12 months in real-world calendar time). Sponsors may separately seek Priority Review designation, which shortens the FDA review goal to 6 months (approximately 8 months total). Because these are distinct regulatory mechanisms, a single application may receive both Accelerated Approval and Priority Review, but Accelerated Approval alone does not confer a faster review timeline.

Historical Context and Evolution in Oncology

The FDA’s accelerated approval pathway originated in the early 1990s in response to the HIV/AIDS public health crisis, when traditional approval timelines were incompatible with urgent patient needs. Codified in 1992, the pathway allows approval based on surrogate endpoints reasonably likely to predict clinical benefit, with a requirement for post‑marketing confirmation. ¹

Oncology soon became a major area of application as advances in cancer biology and molecular characterization enabled earlier measurement of antitumor activity than survival-based endpoints. Academic analyses have shown that tumor response, disease progression, and biomarker changes could often be assessed within months, making oncology particularly well suited to accelerated approval. ¹⁰

Early approvals such as rituximab for relapsed or refractory non‑Hodgkin lymphoma and imatinib for chronic myeloid leukemia established enduring regulatory precedents by demonstrating large, durable treatment effects linked to clear biological mechanisms. These cases reinforced that accelerated approval is most appropriate when strong mechanistic rationale, compelling efficacy, and a credible plan for confirmatory evidence generation are present, a framework that continues to guide FDA decision‑making as oncology drug development has evolved. ⁴

For clarity, the historical evolution of accelerated approval in oncology can be summarized chronologically:

• 1992 – FDA formally establishes the accelerated approval pathway in response to the HIV/AIDS crisis, enabling approval based on surrogate endpoints with required post-marketing confirmation.
• Mid-to-late 1990s – Oncology becomes an early adopter of the pathway as response-based endpoints gain acceptance in hematologic malignancies.
• 1997–2001 – Accelerated approvals of rituximab and imatinib set key precedents for biologically targeted cancer therapies with dramatic and durable responses.
• 2010s – Expansion of accelerated approval in oncology accelerates with the rise of precision medicine, immuno-oncology, and rare molecular subsets.
• 2020 onward – Increased academic scrutiny and FDA enforcement actions emphasize timely confirmatory trials and clinically meaningful benefit, reinforcing the conditional nature of accelerated approval.

Key Statistics and Regulatory Trends Since 2020

Since 2020, accelerated approval in oncology has been under heightened regulatory and academic scrutiny, driven by the growing volume of cancer drugs entering the market through this pathway and increased attention to the timeliness and outcomes of confirmatory trials. FDA approval records and large cohort studies provide a clear, quantitative picture of how central accelerated approval has become to modern oncology drug development.

Key, well-documented statistics and trends include: ^{11, 12. 13}

• 166 accelerated approval indications for 113 anticancer drugs were granted by the FDA between 1992 and 2022, spanning both solid tumors and hematologic malignancies.
• As of August 31, 2024, 61% of oncology accelerated approval indications had converted to regular approval, 18% had been withdrawn, and 20% remained ongoing under accelerated approval.
• The median time to conversion to regular approval was 3.1 years, while the median time to withdrawal was 3.8 years, underscoring the multi‑year nature of confirmatory evidence generation.
• Among oncology accelerated approvals from 2013–2017 with long-term follow-up, 63% ultimately converted, 22% were withdrawn, and 15% remained ongoing after a median of 6.3 years.
• Response-based endpoints dominate pivotal evidence, with response rate alone or combined with duration of response used in the majority of oncology accelerated approvals.
• FDA has actively exercised its authority to withdraw oncology indications when confirmatory trials failed to verify clinical benefit, reinforcing that accelerated approval is explicitly conditional.

Together, these data demonstrate that accelerated approval remains a widely used and viable pathway in oncology, but one that operates within a clearly conditional framework requiring timely, rigorous confirmatory evidence.

Oncology Drug Types Most Likely to Receive Accelerated Approval

FDA approval data and contemporary cohort studies show that accelerated approval in oncology is strongly patterned by both therapeutic modality and disease context, favoring drugs capable of demonstrating early and clinically interpretable antitumor activity in high‑need populations.

Key characteristics of oncology drugs receiving accelerated approval include: ^{1, 14}

• Tumor type distribution: Approximately 66% of accelerated approval indications are for solid tumors and 34% for hematologic malignancies.
• Drug modality: Accelerated approvals frequently involve genome‑targeted therapies (36%) and immune checkpoint inhibitors (23%), reflecting the prominence of precision oncology and immuno‑oncology.
• Endpoint strategy: Pivotal trials most commonly rely on objective response rate and duration of response, particularly in relapsed or refractory disease settings.
• Regulatory context: The majority of oncology accelerated approvals are associated with other FDA expedited programs, including priority review, Breakthrough Therapy designation, and Orphan Drug designation.
• Indication profile:Accelerated approval is most commonly granted in oncology settings characterized by limited or absent effective standard therapies, including advanced or relapsed/refractory disease, rare cancers, and molecularly or biomarker-defined subpopulations.

Collectively, these patterns highlight that accelerated approval in oncology is not driven by disease rarity alone, but by the combination of strong biological rationale, the ability to demonstrate meaningful early efficacy, and a clear path to confirmatory evidence generation.

Eligibility Criteria and Evidentiary Expectations

FDA evaluates accelerated approval within its expedited programs framework for drugs intended to treat serious or life-threatening conditions and address unmet medical need, allowing approval based on surrogate or intermediate clinical endpoints that are reasonably likely to predict clinical benefit. ¹

Key FDA eligibility and evidentiary expectations include: ^{1,15, 16}

• Serious or life-threatening disease context

FDA’s expedited programs apply to serious conditions, which commonly include oncology indications due to disease severity and prognosis.

• Unmet medical need or advantage over available therapy

FDA considers whether there is an absence of adequate available treatment or whether the investigational drug may provide a meaningful therapeutic benefit compared with existing options.

• Use of surrogate or intermediate clinical endpoints

Accelerated approval may rely on endpoints that can be measured earlier than irreversible morbidity or mortality and are reasonably likely to predict clinical benefit.

• Scientific and clinical justification of the endpoint

FDA expects surrogate endpoints to be supported by biological plausibility and available evidence linking the endpoint to meaningful clinical outcomes.

• Magnitude and persuasiveness of the observed effect

When evaluating accelerated approval, FDA considers the strength of the treatment effect observed on the surrogate or intermediate endpoint, recognizing that larger and more convincing effects strengthen the case for approval.

• Feasibility of confirmatory evidence generation

FDA places importance on the sponsor’s ability to conduct confirmatory trials to verify clinical benefit and has issued guidance describing how it evaluates whether such trials are appropriately planned or underway.

Early FDA Alignment as a Determinant of Accelerated Approval Success

Early and proactive alignment with the FDA is a critical determinant of success for Accelerated Approval programs. FDA guidance and regulatory experience consistently emphasize that decisions regarding endpoint acceptability, trial design (including single-arm versus randomized studies), patient population selection, and confirmatory trial feasibility should be discussed and aligned with FDA well before pivotal trial initiation. ⁵ Because accelerated approval relies on surrogate or intermediate clinical endpoints that are only reasonably likely to predict clinical benefit, FDA expects a strong scientific rationale and a clearly articulated plan for post-marketing confirmation. ¹ Failure to obtain early regulatory alignment has been associated with delays in confirmatory evidence generation and post-approval regulatory challenges when confirmatory trials are not adequately designed, feasible, or initiated in a timely manner.¹⁷

Evolving Expectations for Confirmatory Trials Under Accelerated Approval

Recent FDA guidance and regulatory actions have significantly increased expectations for the timing and execution of confirmatory trials supporting accelerated approval. FDA has emphasized that confirmatory trial(s) should generally be underway at the time the marketing application is submitted, and, except in limited circumstances, FDA intends to require confirmatory trial(s) be underway prior to granting accelerated approval. ¹⁸ This evolution reflects FDA’s experience with delayed or infeasible post-approval studies and has been reinforced through initiatives such as Project Confirm, which focuses on timely verification of clinical benefit following accelerated approval.¹ In addition, FDA has issued guidance describing how it interprets whether a confirmatory trial is “underway,” reflecting heightened focus on timely initiation and conduct of confirmatory studies.¹⁹

As a result, the financial, operational, and logistical commitments associated with confirmatory trials are increasingly incurred earlier in development, often well before marketing application submission, because sponsors may need confirmatory enrollment and operational readiness in place to support an accelerated approval action.

FDA also recognizes that confirmatory evidence can be generated through different approaches depending on feasibility and context, including (1) a single trial designed to support accelerated approval and subsequently verify clinical benefit, or (2) two trials, in which case FDA strongly recommends the confirmatory trial be well underway, if not fully enrolled, by the time of the accelerated approval action.⁵

Surrogate Endpoints vs Overall Survival

Overall survival remains the most direct and clinically meaningful measure of benefit in oncology, but its use as a primary endpoint is not always feasible due to long follow-up requirements, effective subsequent therapies, and crossover, particularly in advanced disease settings. FDA guidance therefore acknowledges that surrogate or intermediate endpoints may be appropriate in certain contexts, while emphasizing that their validity must be assessed based on disease- and setting-specific evidence, rather than assumed broadly. ⁵

Importantly, FDA has cautioned that commonly used surrogate endpoints, most notably PFS and objective response rate, do not demonstrate a consistent or universal relationship with overall survival across tumor types and clinical settings. The degree of correlation between PFS and OS varies substantially depending on disease biology, availability of effective post-progression therapies, and trial design features, meaning that improvements in PFS cannot be assumed to translate into survival benefit in all settings. ⁶

Consistent with this variability, FDA analyses and regulatory experience have reinforced that surrogate endpoints used to support accelerated approval must be accompanied by a clear, feasible plan to verify clinical benefit, typically through post-approval trials evaluating endpoints such as OS or other direct measures of patient benefit. Where confirmatory trials fail to demonstrate benefit, or are not completed in a timely manner, accelerated approval indications may remain unresolved for extended periods or be withdrawn. ¹

Disease-specific analyses illustrate this variability. In metastatic breast cancer, a trial-level meta-analysis found that the association between treatment effects on PFS and OS was driven by ≥2nd-line trials and was not significant in 1st-line trials, limiting the reliability of PFS as a universal surrogate for OS across settings.²⁰

Whereas, in case of small-cell lung cancer (SCLC), meta-analysis of phase III trials found a strong correlation between PFS and OS in first-line SCLC (including first-line chemoimmunotherapy), while ORR and DCR did not correlate with OS, supporting PFS (in this specific setting) as a more reliable surrogate than response measures.²¹

Evolving FDA Guidance on Surrogate Endpoints in Multiple Myeloma: MRD and Complete Response

In January 2026, the U.S. Food and Drug Administration (FDA) issued a draft guidance titled Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval, signaling an important evolution in FDA accelerated approval standards for oncology. ²²

Accelerated approval in multiple myeloma has traditionally relied on ORR, often supported by duration of response, to enable earlier patient access to novel therapies. However, with increasingly effective treatments, ORRs now commonly exceed 60%–70% in relapsed or refractory multiple myeloma and approach 90% in newly diagnosed disease, reducing the ability of ORR to distinguish meaningful clinical benefit without very large trials. FDA has recognized that more sensitive surrogate endpoints, such as minimal residual disease (MRD), may better support continued expeditious drug development in multiple myeloma.

The draft guidance outlines FDA’s current thinking on the use of MRD negativity and complete response (CR) as potential primary endpoints for accelerated approval, provided they are measured using validated assays and supported by strong biological and clinical justification. FDA emphasizes that accelerated approval based on MRD or CR remains conditional and requires timely post-marketing confirmatory trials to verify clinical benefit, such as progression-free or overall survival.

Key Takeaways

• Accelerated approval is now a cornerstone of oncology drug development, accounting for the majority of FDA accelerated approvals since 2020.
• FDA accelerated approval is a S.-specific regulatory mechanism. Sponsors planning a global submission strategy generally need an evidence plan that can satisfy non-U.S. regulators and, critically, health technology assessment (HTA) and payer requirements.
• Surrogate endpoints must be both biologically plausible and clinically meaningful; modest or short-lived responses are increasingly insufficient.
• Early initiation and timely completion of confirmatory trials are essential, as FDA has shown increased willingness to withdraw approvals when benefit is not verified.
• Confirmatory trials now need to be operational earlier for Accelerated Approval.
  FDA increasingly expects confirmatory studies to be underway before approval, shifting cost, planning, and execution to much earlier in development.
• Surrogate endpoints require disease-specific justification and timely confirmation.
  Because surrogates such as PFS do not consistently predict overall survival, accelerated approval must be paired with a clear, feasible path to verify clinical benefit.
• Successful accelerated approval programs are strategically designed from the outset, integrating regulatory engagement, endpoint selection, and operational readiness.
• Accelerated approval is not a shortcut, but a conditional commitment that demands scientific rigor, executional excellence, and long-term planning.
• FDA is increasingly issuing disease-specific guidance on surrogate endpoints, as illustrated by recent draft guidance on MRD and complete response in multiple myeloma, signaling both greater regulatory clarity and higher evidentiary expectations for accelerated approval.

How Arc Nouvel Supports Accelerated Approval Success

Analyses of oncology accelerated approvals published since 2020 identify several consistent features of successful programs. These include strong biological rationale, substantial and durable treatment effects, early FDA engagement, and proactive initiation of confirmatory trials.

Founded by global pharmaceutical leader Dr. Nageatte Ibrahim, Arc Nouvel Clinical Development Consulting LLC partners with pharmaceutical and biotechnology companies to navigate the complexities of accelerated approval with clarity and confidence. As a boutique consultancy specializing in oncology clinical development, we provide strategic guidance across early and late phases, integrating regulatory insight with operational excellence.

Our team and global advisory board bring decades of experience in FDA interactions, pivotal trial design, and post-marketing strategy. We support sponsors in assessing accelerated approval feasibility, aligning surrogate endpoints with disease biology, designing confirmatory trials, and making high-impact clinical development decisions that withstand regulatory scrutiny.